Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 26, 2020
Beyond Antibodies: The DARPin® Drug PlatformMichael T Stumpp, Keith M Dawson, H Kaspar BinzOncotarget|December 13, 2017
MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor modelsUlrike Fiedler, Savira Ekawardhani, Andreas Cornelius, et al.Blood|February 7, 2009
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignanciesAimable Nahimana, Antoine Attinger, Dominique Aubry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.Cancer Immunology Research|April 29, 2024
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem CellsMatteo Bianchi, Christian Reichen, Amelie Croset, et al.Nature Biotechnology|July 21, 2022
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variantsSylvia Rothenberger, Daniel L Hurdiss, Marcel Walser, et al.Pageof 1